Related Experiment Video
Updated: Aug 25, 2026

Implementation of Portable Emissions Measurement Systems (PEMS) for the Real-driving Emissions (RDE) Regulation in Europe
Published on: December 4, 2016
The impact of CE marking: is there a down side?
1Evaluation and Standards Laboratory, CPHL, 61 Colindale Avenue, London NW9 5DE.
Insights
The In Vitro Diagnostic Device Directive (IVDD) should not apply to in-house laboratory assays, as compliance is impractical and costly. Upholding this interpretation risks negatively impacting UK healthcare services and patient health.
Area of Science:
- Clinical Pathology
- Regulatory Science
- Medical Laboratory Science
Background:
- The In Vitro Diagnostic Device Directive (IVDD) aims to regulate medical devices placed on the market.
- Healthcare institutions produce in-house assays not intended for commercial sale.
Purpose of the Study:
- To evaluate the implications of the MHRA's interpretation of the IVDD on in-house laboratory assays.
- To highlight the impracticality and negative consequences of applying the IVDD to assays developed within healthcare settings.
Main Methods:
- Analysis of the scope and intent of the IVDD.
- Assessment of the potential impact of MHRA's interpretation on pathology services across the UK.
Main Results:
- The IVDD was not designed for in-house assays, making compliance impractical for healthcare institutions.
- The MHRA's interpretation could divert funds, stifle innovation, and negatively affect pathology services and national health.
Conclusions:
- Applying the IVDD to in-house assays is detrimental to the efficacy of UK pathology services.
- The principles of the IVDD are sound for market-placed IVDs but not for internal laboratory use.
Abstract:
In summary, the IVDD was never intended to include in house assays produced within healthcare institutions, and it was clear to the authors that it would be impractical for them to comply with the Directive. The above points apply to all pathology specialties, all of which will be profoundly affected if the MHRA's interpretation of the Directive is upheld. It must be appreciated that, as well as affecting a large number of specialist and reference laboratories, many NHS laboratories perform in house assays on samples provided by other trusts. The costs involved in complying with the IVDD, if the present MHRA interpretation is upheld, will divert funds away from other healthcare initiatives and will inevitably stifle further development of specialist in house assays which make an immense contribution to our health services. The principles of the Directive are sound and its introduction will have a beneficial affect on pathology due to better regulation of IVDs, which are placed on the market. However, applying the Directive to in house assays can only be detrimental to the efficacy of pathology services across the UK and therefore have a negative affect on the health of the nation.
Related Concept Videos
Halo Effect
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Soundness of Cement
Bacterial Signaling
Deleterious Substances in Aggregate
Another type of impurity is clay and fine material that...
FDA Approved Drugs: Changes to Approved Drugs
